Initial Statement of Beneficial Ownership (3)
November 07 2019 - 6:09PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Wall Brett A. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/1/2019
|
3. Issuer Name and Ticker or Trading Symbol
Medtronic plc [MDT]
|
|
(Last)
(First)
(Middle)
710 MEDTRONIC PARKWAY, LC300 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
EVP & Group Pres Restora Thera / |
|
(Street)
MINNEAPOLIS, MN 55432
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Ordinary Shares | 13075 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | 10/28/2020 (2) | 10/28/2029 | Ordinary Shares | 22579 | $106.22 | D | |
| Stock Option (Right to Buy) | 8/3/2016 (2) | 8/3/2025 | Ordinary Shares | 11154 | $78.00 | D | |
| Stock Option (Right to Buy) | 8/3/2016 (2) | 8/3/2025 | Ordinary Shares | 1283 | $78.00 | D | |
| Stock Option (Right to Buy) | 8/1/2017 (2) | 8/1/2026 | Ordinary Shares | 11356 | $88.06 | D | |
| Stock Option (Right to Buy) | 8/1/2017 (2) | 8/1/2026 | Ordinary Shares | 1136 | $88.06 | D | |
| Stock Option (Right to Buy) | 7/31/2018 (2) | 7/31/2027 | Ordinary Shares | 11910 | $83.97 | D | |
| Stock Option (Right to Buy) | 7/31/2018 (2) | 7/31/2027 | Ordinary Shares | 1191 | $83.97 | D | |
| Stock Option (Right to Buy) | 7/30/2019 (2) | 7/30/2028 | Ordinary Shares | 16946 | $89.08 | D | |
| Stock Option (Right to Buy) | 7/30/2019 (2) | 7/30/2028 | Ordinary Shares | 1695 | $89.08 | D | |
| Stock Option (Right to Buy) | 7/29/2020 (2) | 7/29/2029 | Ordinary Shares | 24223 | $103.26 | D | |
| Stock Option (Right to Buy) | 7/29/2020 (2) | 7/29/2029 | Ordinary Shares | 1615 | $103.26 | D | |
| Stock Option (Right to Buy) | 12/2/2014 (2) | 12/1/2023 | Ordinary Shares | 12300 | $47.00 | D | |
| Stock Option (Right to Buy) | 6/29/2018 (3) | 1/27/2025 | Ordinary Shares | 8018 | $74.84 | D | |
| Explanation of Responses: |
| (1) | Includes grants of restricted stock units which vest on the listed date and for the listed number of shares if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth measured over the three most recently completed fiscal years exceeds a 3% cumulative compound annual growth rate (as determined by the Compensation Committee): (i) 3,129 restricted stock units that vest on 7/31/2020; (ii) 2,884 restricted stock units that vest on 7/30/2021; and (iii) 7,062 restricted stock units that vest on 7/29/2022. |
| (2) | These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. |
| (3) | This option became exercisable on June 29, 2018, subject to Medtronic plc's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Wall Brett A.
710 MEDTRONIC PARKWAY
LC300
MINNEAPOLIS, MN 55432 |
|
| EVP & Group Pres Restora Thera |
|
Signatures
|
| /s/ Perry F. Sekus, attorney-in-fact | | 11/7/2019 |
| **Signature of Reporting Person | Date |
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024
